{"schema_version":"secwatch.filing_event.v1","accession":"0001641489-24-000063","form_type":"8-K","ticker":"VTVT","cik":"0001641489","company_name":"vTv Therapeutics Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.920081+00:00","generated_at":"2026-05-31T10:58:27.498505+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"vTv Therapeutics Q2 2024 net loss $5.2M; FDA places clinical hold on cadisegliatin T1D trial","bullets":["Net loss $5.2M ($0.81/sh) vs $5.6M ($2.69/sh) in Q2 2023; cash $45.5M up from $9.4M year-end.","FDA placed clinical hold on cadisegliatin T1D program in July; no patients dosed in pivotal trial.","Expanded HPP737 license with Newsoara to global license contingent on $20M upfront fee.","Cantex received Orphan Drug Designation for azeliragon in pancreatic cancer.","R&D expenses decreased to $3.4M from $4.7M; G&A increased to $3.7M from $3.3M."],"urls":{"canonical":"https://secwatch.observer/filing/0001641489-24-000063","json":"https://secwatch.observer/filing/0001641489-24-000063.json","markdown":"https://secwatch.observer/filing/0001641489-24-000063.md","text":"https://secwatch.observer/filing/0001641489-24-000063.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641489/000164148924000063/0001641489-24-000063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641489/000164148924000063/vtvt-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:58:27.498505+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}